Nicholas P. Restifo

Nicholas P. Restifo's AcademicInfluence.com Rankings

Nicholas P. Restifo

Biology

#4504

World Rank

#6707

Historical Rank

Biochemistry

#469

World Rank

#551

Historical Rank

biology Degrees

Download Badge

Biology

Nicholas P. Restifo's Degrees

PhD Biomedical Sciences University of California, San Francisco
Bachelors Biochemistry University of California, San Diego

Why Is Nicholas P. Restifo Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Nicholas P. Restifo's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Cancer immunotherapy: moving beyond current vaccines (2004) (2944)
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes (2002) (2901)
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes (2006) (2575)
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma (1998) (1897)
Adoptive cell transfer as personalized immunotherapy for human cancer (2015) (1767)
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. (2005) (1640)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma (2003) (1591)
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy (2011) (1551)
Adoptive cell transfer: a clinical path to effective cancer immunotherapy (2008) (1522)
A human memory T-cell subset with stem cell-like properties (2011) (1505)
Adoptive immunotherapy for cancer: harnessing the T cell response (2012) (1487)
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. (2011) (1449)
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. (2009) (1338)
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. (2008) (1283)
Natural selection of tumor variants in the generation of “tumor escape” phenotypes (2002) (1046)
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells (2005) (998)
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. (2005) (969)
Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells (2003) (945)
Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy (2013) (943)
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. (2005) (929)
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. (2005) (919)
Adoptive immunotherapy for cancer: building on success (2006) (872)
Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells (2009) (843)
Tumor-specific Th17-polarized cells eradicate large established melanoma. (2008) (795)
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts (2010) (748)
CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells (2005) (735)
T helper 17 cells promote cytotoxic T cell activation in tumor immunity. (2009) (726)
Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function (2005) (722)
Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. (2013) (677)
Human memory T cells: generation, compartmentalization and homeostasis (2013) (675)
Identification of human cancers deficient in antigen processing (1993) (657)
Predominant Role for Directly Transfected Dendritic Cells in Antigen Presentation to CD8+ T Cells after Gene Gun Immunization (1998) (614)
Defining ‘T cell exhaustion’ (2019) (604)
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response (2014) (592)
Identification of essential genes for cancer immunotherapy (2017) (582)
Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. (2000) (569)
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. (2002) (564)
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells (2004) (553)
T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. (2011) (547)
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. (2010) (544)
TH17 cells in tumour immunity and immunotherapy (2010) (541)
Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. (1996) (516)
gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand (1998) (505)
Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma (2005) (500)
CD8+ T‐cell memory in tumor immunology and immunotherapy (2006) (499)
Paths to stemness: building the ultimate antitumour T cell (2012) (482)
Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. (2007) (465)
Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. (2015) (448)
Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. (1999) (446)
Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. (2005) (434)
Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. (1999) (421)
Ionic immune suppression within the tumour microenvironment limits T cell effector function (2016) (420)
Th17 cells are long lived and retain a stem cell-like molecular signature. (2011) (402)
Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma (2010) (401)
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. (2008) (400)
Adoptively transferred effector cells derived from naïve rather than central memory CD8+ T cells mediate superior antitumor immunity (2009) (369)
Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. (1998) (360)
Classification of current anticancer immunotherapies (2014) (357)
Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism (2018) (350)
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. (2011) (349)
Essentials of Th17 cell commitment and plasticity. (2013) (336)
DNA and RNA-based vaccines: principles, progress and prospects. (1999) (336)
B16 as a Mouse Model for Human Melanoma (2000) (336)
Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. (1998) (334)
Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine (2001) (328)
Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. (1997) (326)
Bach2 represses effector programmes to stabilize Treg-mediated immune homeostasis (2013) (325)
Acquired resistance to immunotherapy and future challenges (2016) (324)
Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go? (2006) (320)
Cancer therapy using a self-replicating RNA vaccine (1999) (318)
Cellular constituents of immune escape within the tumor microenvironment. (2012) (313)
Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. (1991) (306)
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. (2011) (299)
Stretch-Enhancers Delineate Disease-Associated Regulatory Nodes in T Cells (2014) (297)
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. (2010) (296)
Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia (2013) (294)
Therapeutic cancer vaccines: are we there yet? (2011) (291)
CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma (2010) (289)
Prospects for gene-engineered T cell immunotherapy for solid cancers (2016) (288)
Superior T memory stem cell persistence supports long-lived T cell memory. (2013) (287)
Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways (2003) (287)
T cell stemness and dysfunction in tumors are triggered by a common mechanism (2019) (284)
Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. (2017) (282)
Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. (2011) (272)
Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy. (2016) (271)
High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. (2006) (269)
Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape (2000) (267)
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. (2002) (265)
Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. (2015) (260)
MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. (2013) (260)
High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens (2003) (259)
Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. (1996) (259)
Antigen processing in vivo and the elicitation of primary CTL responses. (1995) (257)
Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma (2015) (255)
Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. (2016) (255)
Sorting Through Subsets: Which T-Cell Populations Mediate Highly Effective Adoptive Immunotherapy? (2012) (253)
Epigenetic control of CD8+ T cell differentiation (2018) (250)
Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice (2011) (244)
Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. (2009) (241)
Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. (1995) (240)
Molecular characterization of defective antigen processing in human prostate cancer. (1995) (239)
Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells (2010) (239)
Type 17 CD8+ T cells display enhanced antitumor immunity. (2009) (235)
Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. (2010) (234)
Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice (2012) (233)
Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. (2011) (229)
Adoptive immunotherapy of cancer using CD4(+) T cells. (2009) (228)
Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines (2008) (226)
CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. (2005) (213)
Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. (2007) (212)
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. (2010) (209)
Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. (2006) (209)
Biopsychosocial characteristics of children who later murder: a prospective study. (1985) (196)
Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. (1999) (194)
Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. (2013) (192)
Cutting Edge: CD4+ T Cell Control of CD8+ T Cell Reactivity to a Model Tumor Antigen (2000) (189)
Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche (2016) (186)
Lineage relationship of effector and memory T cells. (2013) (186)
Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. (1995) (183)
BACH2 regulates CD8+ T cell differentiation by controlling access of AP-1 factors to enhancers (2016) (181)
Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma (2019) (180)
CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. (1998) (180)
An autologous oral DNA vaccine protects against murine melanoma. (2000) (179)
A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability (1992) (176)
Reassessing target antigens for adoptive T cell therapy (2013) (176)
Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells (2012) (175)
Regulation of nucleosome landscape and transcription factor targeting at tissue-specific enhancers by BRG1. (2011) (175)
Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. (1997) (173)
Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. (2015) (172)
Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition (2008) (172)
T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy (2013) (172)
Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. (2000) (169)
Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. (1997) (169)
Self-Tolerance to the Murine Homologue of a Tyrosinase-Derived Melanoma Antigen (2000) (168)
Identification of CD4+ T Cell Epitopes from NY-ESO-1 Presented by HLA-DR Molecules (2000) (165)
Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity. (2000) (165)
TH17 cells in tumour immunity and immunotherapy (2011) (165)
Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers (2019) (161)
A TCR Targeting the HLA-A*0201–Restricted Epitope of MAGE-A3 Recognizes Multiple Epitopes of the MAGE-A Antigen Superfamily in Several Types of Cancer (2011) (157)
Immune Evasion by Murine Melanoma Mediated through CC Chemokine Receptor-10 (2003) (151)
Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits CD8+ T cell memory formation (2011) (148)
Human melanoma cells do not express Fas (Apo-1/CD95) ligand. (1999) (148)
Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. (1996) (147)
A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. (2014) (144)
Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. (1996) (141)
Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors (2015) (141)
Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. (1999) (140)
IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. (1996) (140)
Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. (2000) (138)
Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I. (1993) (136)
Identification of a MHC Class II-Restricted Human gp100 Epitope Using DR4-IE Transgenic Mice (2000) (136)
De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. (2006) (136)
Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity (2008) (132)
Dendritic Cells Strongly Boost the Antitumor Activity of Adoptively Transferred T Cells In vivo (2004) (130)
Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. (2017) (130)
The promise of nucleic acid vaccines (2000) (130)
Developing neoantigen-targeted T cell–based treatments for solid tumors (2019) (130)
Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response. (1991) (129)
Bcl-2 overexpression enhances tumor-specific T-cell survival. (2005) (129)
Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. (2000) (128)
IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. (1995) (127)
Toll-like Receptors in Tumor Immunotherapy (2007) (126)
Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance (2015) (126)
Vaccine-Stimulated, Adoptively Transferred CD8+ T Cells Traffic Indiscriminately and Ubiquitously while Mediating Specific Tumor Destruction1 (2004) (126)
Wnt/β-Catenin Signaling in T-Cell Immunity and Cancer Immunotherapy (2010) (124)
The Bone Marrow Protects and Optimizes Immunological Memory during Dietary Restriction (2019) (123)
Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. (2004) (122)
Retinoic acid controls the homeostasis of pre-cDC–derived splenic and intestinal dendritic cells (2013) (122)
The interplay of effector and regulatory T cells in cancer. (2015) (120)
Consensus nomenclature for CD8+ T cell phenotypes in cancer (2015) (118)
Immunization of Patients with Metastatic Melanoma Using Both Class I- and Class II-Restricted Peptides from Melanoma-Associated Antigens (2003) (118)
Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity (2010) (115)
Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. (2003) (114)
Increased Immunogenicity of an Anchor-Modified Tumor-Associated Antigen Is Due to the Enhanced Stability of the Peptide/MHC Complex: Implications for Vaccine Design1 (2005) (114)
Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. (2005) (113)
Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy. (1997) (111)
Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. (1997) (110)
Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. (1997) (106)
Immune Selection of Hot-Spot β2-Microglobulin Gene Mutations, HLA-A2 Allospecificity Loss, and Antigen-Processing Machinery Component Down-Regulation in Melanoma Cells Derived from Recurrent Metastases following Immunotherapy1 (2005) (105)
Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells (2013) (104)
Cancer vaccines: progress reveals new complexities. (2002) (103)
Uncoupling T‐cell expansion from effector differentiation in cell‐based immunotherapy (2014) (103)
Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. (2003) (99)
Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factor. (1993) (99)
Flu: The Story of the Great Influenza Pandemic of 1918 and the Search for the Virus that Caused It (2000) (98)
Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. (2009) (97)
Nutrient Competition: A New Axis of Tumor Immunosuppression (2015) (97)
miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines (2014) (97)
Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. (2007) (97)
BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency (2017) (96)
Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition. (2007) (94)
Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. (2005) (93)
Intensity of the Vaccine-Elicited Immune Response Determines Tumor Clearance (2002) (93)
Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. (1997) (92)
T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy (2019) (92)
Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails (2013) (90)
Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. (1996) (89)
Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy (2012) (88)
Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. (2018) (88)
Immunological and Antitumor Effects of IL-23 as a Cancer Vaccine Adjuvant1 (2006) (87)
Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. (2002) (87)
Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice. (1994) (86)
Lineage relationship of CD8+ T cell subsets is revealed by progressive changes in the epigenetic landscape (2015) (86)
Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge (1994) (86)
Genetic Engineering of Murine CD8+ and CD4+ T Cells for Preclinical Adoptive Immunotherapy Studies (2011) (85)
Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting (2016) (85)
Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice. (2013) (84)
Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an In vitro melanoma model (1999) (83)
Interleukin-2-Dependent Mechanisms of Tolerance and Immunity In Vivo1 (2006) (83)
The transcription factor c-Myb regulates CD8+ T cell stemness and antitumor immunity (2018) (83)
Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines. (2004) (82)
Both CD4 and CD8 T Cells Mediate Equally Effective In Vivo Tumor Treatment When Engineered with a Highly Avid TCR Targeting Tyrosinase (2010) (82)
Immunization against endogenous retroviral tumor-associated antigens. (2001) (79)
Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice (2011) (78)
The new vaccines: building viruses that elicit antitumor immunity. (1996) (77)
Metabolic reprograming of anti-tumor immunity. (2017) (76)
Countering the 'counterattack' hypothesis (2001) (75)
T-Cell Receptor Gene Therapy of Established Tumors in a Murine Melanoma Model (2008) (75)
The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells (2015) (75)
Identification of a CD 11 b 1 / Gr-1 1 / CD 31 1 myeloid progenitor capable of activating or suppressing CD 8 1 T cells (2000) (75)
Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy? (2002) (74)
Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma. (2015) (73)
Programming CD8+ T cells for effective immunotherapy. (2006) (73)
Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies. (2020) (73)
Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". (2000) (73)
T cell–tumor cell: a fatal interaction? (1998) (70)
Pharmacologic Induction of CD8+ T Cell Memory: Better Living Through Chemistry (2009) (68)
Developing recombinant and synthetic vaccines for the treatment of melanoma. (1999) (68)
The future of interleukin-2: enhancing therapeutic anticancer vaccines. (2000) (68)
Cell Transfer Therapy for Cancer: Lessons from Sequential Treatments of a Patient With Metastatic Melanoma (2003) (67)
Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens. (1997) (65)
The effects of euglycemic hyperinsulinemia and amino acid infusion on regional and whole body glucose disposal in man. (1991) (64)
Ribosomal Proteins Regulate MHC Class I Peptide Generation for Immunosurveillance. (2019) (63)
HLA Associations in the Antitumor Response Against Malignant Melanoma (1995) (63)
Erratum: TH 17 cells in tumour immunity and immunotherapy (Nature Reviews Immunology (2010) 10 (248-256)) (2011) (63)
Collapse of the tumor stroma is triggered by IL-12 induction of Fas. (2013) (62)
Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses. (2006) (61)
T-cell recognition of human melanoma antigens. (1993) (61)
A cleavage product of Polycystin-1 is a mitochondrial matrix protein that affects mitochondria morphology and function when heterologously expressed (2018) (61)
Type I Interferons are essential for the efficacy of replicase-based DNA vaccines. (2006) (60)
Glucocorticoids Do Not Inhibit Antitumor Activity of Activated CD8+ T Cells (2005) (60)
Moving T memory stem cells to the clinic. (2013) (59)
Interleukin-2-dependent mechanisms of tolerance and immunity in vivo (2006) (59)
Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses. (1995) (58)
The antiviral enzymes PKR and RNase L suppress gene expression from viral and non-viral based vectors. (1999) (57)
Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors (2013) (57)
CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent. (2006) (55)
The Stoichiometric Production of IL-2 and IFN-γ mRNA Defines Memory T Cells That Can Self-Renew After Adoptive Transfer in Humans (2012) (55)
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer (2012) (54)
The in vivo expansion rate of properly stimulated transferred CD8+ T cells exceeds that of an aggressively growing mouse tumor. (2006) (54)
Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers (2016) (52)
Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens. (1999) (52)
An engineered IL-2 partial agonist promotes CD8+ T cell stemness (2020) (51)
STING agonist promotes CAR T cell trafficking and persistence in breast cancer (2020) (51)
Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy (2020) (50)
Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens (2020) (50)
Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases (2006) (50)
Novel “Elements” of Immune Suppression within the Tumor Microenvironment (2017) (49)
Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines. (1994) (48)
Evaluation of Prime/Boost Regimens Using Recombinant Poxvirus/Tyrosinase Vaccines for the Treatment of Patients with Metastatic Melanoma (2006) (47)
Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer (2004) (47)
Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen. (1998) (47)
GILT Accelerates Autoimmunity to the Melanoma Antigen Tyrosinase-Related Protein 1 (2010) (46)
Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. (1999) (46)
In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells (2011) (45)
Fas/CD95 prevents autoimmunity independently of lipid raft localization and efficient apoptosis induction (2016) (44)
The transcription factor BACH2 promotes tumor immunosuppression. (2016) (44)
Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL. (1995) (43)
Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. (2020) (41)
Host conditioning with IL-1β improves the antitumor function of adoptively transferred T cells (2019) (40)
Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. (2008) (40)
Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA. (1993) (38)
Cross‐priming utilizes antigen not available to the direct presentation pathway (2006) (38)
Microbiota Modulation of Myeloid Cells in Cancer Therapy (2015) (38)
Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen. (1999) (37)
Viral Sequestration of Antigen Subverts Cross Presentation to CD8+ T Cells (2009) (36)
Cancer immunotherapy. (2008) (36)
Generation of Tumor Antigen-Specific iPSC-Derived Thymic Emigrants Using a 3D Thymic Culture System. (2018) (35)
Increased Frequency of Suppressive Regulatory T Cells and T Cell-Mediated Antigen Loss Results in Murine Melanoma Recurrence (2012) (35)
Creating therapeutic cancer vaccines: notes from the battlefield. (2001) (34)
Altered CD8+ T-Cell Responses When Immunizing With Multiepitope Peptide Vaccines (2006) (34)
Assumptions of the tumor 'escape' hypothesis. (2002) (34)
Reprogramming antitumor immunity. (2014) (33)
Does IL-17 promote tumor growth? (2009) (33)
Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer. (1998) (32)
Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation (2019) (29)
An effective mouse model for adoptive cancer immunotherapy targeting neoantigens. (2019) (29)
HPV-targeted tumor-infiltrating lymphocytes for cervical cancer. (2014) (29)
Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination. (2009) (29)
Anti‐Tumor Activity of Cytotoxic T Lymphocytes Elicited with Recombinant and Synthetic Forms of a Model Tumor‐Associated Antigen (1995) (29)
MHC Class II Presentation of gp100 Epitopes in Melanoma Cells Requires the Function of Conventional Endosomes and Is Influenced by Melanosomes1 (2008) (29)
Transcriptional profiles reveal a stepwise developmental program of memory CD8(+) T cell differentiation. (2015) (28)
Different Adjuvanticity of Incomplete Freund's Adjuvant Derived From Beef or Vegetable Components in Melanoma Patients Immunized With a Peptide Vaccine (2010) (27)
Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function. (2002) (27)
MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells (2002) (27)
Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen. (2001) (26)
Normal Tissue Depresses While Tumor Tissue Enhances Human T Cell Responses In Vivo to a Novel Self/Tumor Melanoma Antigen, OA1 (2003) (26)
Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest (2014) (25)
Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-alpha. (1994) (25)
Use of standard criteria for assessment of cancer vaccines. (2005) (25)
In vivo activity of tumor necrosis factor (TNF) mutants. Secretory but not membrane-bound TNF mediates the regression of retrovirally transduced murine tumor. (1992) (25)
Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity. (2010) (24)
DNA vaccines and apoptosis: to kill or not to kill? (2003) (24)
Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade (2020) (23)
Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD 8 + T cells (2007) (22)
Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models (2020) (22)
The Cish SH2 domain is essential for PLC-γ1 regulation in TCR stimulated CD8+ T cells (2018) (22)
High-avidity Autoreactive CD4+ T Cells Induce Host CTL, Overcome Tregs and Mediate Tumor Destruction (2009) (21)
Mg2+ regulation of kinase signaling and immune function (2019) (21)
Immunologic ignorance of vascular endothelial cells expressing minor histocompatibility antigen. (2008) (21)
Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68 (2011) (21)
Constitutive Lck Activity Drives Sensitivity Differences between CD8+ Memory T Cell Subsets (2016) (21)
Identification of the Genomic Insertion Site of Pmel-1 TCR α and β Transgenes by Next-Generation Sequencing (2014) (20)
Mouse Model for Pre‐Clinical Study of Human Cancer Immunotherapy (2015) (20)
Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8+ T cells without host preconditioning (2016) (20)
Defective major histocompatibility complex class I expression in a sarcomatoid renal cell carcinoma cell line. (1995) (20)
TSCOT + Thymic Epithelial Cell-Mediated Sensitive CD4 Tolerance by Direct Presentation (2008) (19)
Vaccines to die for (2001) (18)
Route of immunization and the therapeutic impact of recombinant anticancer vaccines. (1997) (18)
A "big data" view of the tumor "immunome". (2013) (18)
Can antitumor immunity help to explain "oncogene addiction"? (2010) (17)
ASXL3 Is a Novel Pluripotency Factor in Human Respiratory Epithelial Cells and a Potential Therapeutic Target in Small Cell Lung Cancer. (2017) (17)
Enhancing the recognition of tumour associated antigens. (1994) (17)
Hierarchy, Tolerance, and Dominance in the Antitumor T-Cell Response. (2001) (16)
Double or nothing on cancer immunotherapy (2013) (16)
The Role of Glycogen Synthase Kinase 3 in Regulating IFN-b–Mediated IL-10 Production (2010) (16)
Retroviral transduction of interferon-γ cDNA into a nonimmunogenic murinefibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor (1993) (16)
Arginine Arms T Cells to Thrive and Survive. (2016) (15)
Silencing stemness in T cell differentiation (2018) (15)
Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responses. (2000) (15)
Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization. (1998) (15)
IFN‐γ‐receptor signaling ameliorates transplant vasculopathy through attenuation of CD8+ T‐cell‐mediated injury of vascular endothelial cells (2010) (15)
The power and pitfalls of IL-12. (2012) (15)
The next wave of recombinant and synthetic anticancer vaccines. (1995) (15)
Enhanced expression of HLA-A,B,C and inducibility of TAP-1, TAP-2, and HLA-A,B,C by interferon-gamma in a multidrug-resistant small cell lung cancer line. (1994) (15)
Big bang theory of stem-like T cells confirmed. (2014) (14)
Memoirs of a reincarnated T cell. (2013) (13)
Immunotherapy: Treatment of aggressive lymphomas with anti-CD19 CAR T cells (2014) (13)
Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest (1994) (12)
Antigen‐specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC (2002) (12)
Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development (2000) (12)
T cell receptor affinity and avidity defines antitumor response and autoimmunity in T cell immunotherapy (2013) (12)
CD4CD25 T Regulatory Cells, Immunotherapy of Cancer, and Interleukin-2 (2005) (11)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
Strength in Numbers: Identifying Neoantigen Targets for Cancer Immunotherapy (2020) (10)
The kinase DYRK 1 A reciprocally regulates the differentiation of Th 17 and regulatory T cells (2015) (10)
Reply to "Cancer vaccines: pessimism in check" (2004) (9)
Polymeric Structure and Host Toll-like Receptor 4 Dictate Immunogenicity of NY-ESO-1 Antigen in Vivo* (2011) (8)
Mg 2+ regulation of kinase signaling and immune function (2019) (8)
The multiple uses of viruses for studying antigen processing (1993) (8)
Reply to: “β-catenin does not regulate memory T cell phenotype” (2010) (7)
Response to Comment on “Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma” (2006) (7)
Erratum: Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling (Journal of Clinical Investigation (2007) 117, (2197-2204) DOI:10.1172/JCI32205) (2007) (7)
Definitive hematopoietic stem/progenitor cells from human embryonic stem cells through serum/feeder-free organoid-induced differentiation (2020) (7)
Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy (2019) (7)
regression and targets normal tissues expressing cognate antigen Gene therapy with human and mouse T-cell receptors mediates cancer (2009) (7)
Enhanced T-cell activation and differentiation in lymphocytes from transgenic mice expressing ubiquitination-resistant 2KR LAT molecules (2015) (7)
Next generation immunotherapy: enhancing stemness of polyclonal T cells to improve anti-tumor activity. (2021) (7)
Cancer Vaccines '98: a reductionistic approach (1998) (6)
Customizing Functionality and Payload Delivery for Receptor-Engineered T Cells (2016) (6)
Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting (2013) (6)
IDENTIFICATION OF HUMAN CANCERS DEFECTIVE IN ANTIGEN PROCESSING (1993) (5)
Identification of Small Molecule Enhancers of Immunotherapy for Melanoma (2020) (5)
Targeting Akt in cell transfer immunotherapy for cancer (2016) (4)
Erratum: In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells (Cancer Immunol Immunother DOI 10.1007/s00262-011-0977-7) (2011) (4)
Cancer vaccines and immunotherapy: Poxviruses as vectors for cancer immunotherapy (2000) (4)
Using Human Induced Pluripotent Stem Cells for the Generation of Tumor Antigen-specific T Cells. (2019) (4)
Peptide / MHC Complex : Implications for Is Due to the Enhanced Stability of the Anchor-Modified Tumor-Associated Antigen Increased Immunogenicity of an (2005) (4)
Cancer Therapy : Preclinical Determinants of Successful CD 8 þ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice (2011) (4)
Recombinant anticancer vaccines. (1996) (4)
Adoptive T cell therapy of cancer. (2009) (4)
Tolerance and Immunity In Vivo Interleukin-2-Dependent Mechanisms of (2006) (3)
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer (2012) (3)
333 Targeting the apical intracellular checkpoint CISH unleashes T cell neoantigen reactivity and effector program (2020) (3)
5-AZA-2′-Deoxycytidine in Cancer Immunotherapy: A Mouse to Man Story (2007) (3)
Local Delivery of lnterleukin-12 using T cells Targeting Vascular Endothelial Growth Factor Receptor-2 Eradicates Multiple Vascularized Tumors in Mice (2012) (3)
Identifying the source of tumour-infiltrating T cells (2019) (3)
Clinical scale zinc finger nuclease (ZFN)-driven gene-editing of PD-1 in tumor infiltrating lymphocytes (TIL) for the potential treatment of metastatic melanoma (2014) (3)
GENE-MODIFICATION CORRECTS AN ANTIGEN PRESENTATION DEFECT IN A NON-IMMUNOGENIC SARCOMA AND ELICITS CD8+ T CELLS REACTIVE AGAINST THE WILD-TYPE TUMOR: IMPLICATIONS FOR THE IMMUNOTHERAPY OF CANCER (1992) (3)
Multiply restimulated human thymic regulatory T cells express distinct signature regulatory T-cell transcription factors without evidence of exhaustion. (2021) (3)
Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts (2017) (3)
Genome-wide Screens Identify Lineage- and Tumor Specific-Genes Modulating MHC-I and MHC-II Immunosurveillance in Human Lymphomas (2020) (3)
Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts (2018) (3)
A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants. (2019) (2)
Three case reports of a single homicidal adolescent. (1985) (2)
Erratum: An autologous oral DNA vaccine protects against murine melanoma (Proceedings of the National Academy of Sciences of the United States of America (May 9, 2000) 97 (10) (5492-5497)) (2000) (2)
Tumor Challenge andInduces Protective Immunity to Infectious andHumoral and Cellular Immune Responses CD 40 Ligand / Trimer DNA Enhances Both (1998) (2)
BACH2 represses effector programmes to stabilize Treg-mediated immune homeostasis - a new target in tumor immunotherapy? (2013) (2)
Microbiota Modulation of Myeloid Cells in Cancer (2015) (2)
Nine lives for TH9s? (2012) (2)
Elevated potassium levels suppress T cell activation within tumors (2015) (2)
NMDA Receptor-PSD-95 Protein Interactions Treatment of Ischemic Brain Damage by Perturbing (2006) (2)
Viruses Encoding the Anchor-modified gp 100 Melanoma Antigen Can Generate Antitumor Immune Responses in Patients with Metastatic Melanoma (2003) (2)
Role for skin-associated microbiota in development of endogenous anti-melanocyte immunity in vitiligo (2017) (2)
Self-organized yolk sac-like organoids allow for scalable generation of multipotent hematopoietic progenitor cells from human induced pluripotent stem cells (2021) (1)
Immunization against Endogenous Retroviral Tumor-associated Antigens 1 (2001) (1)
370 The Epi-RTMtechnology produces a polyclonal TIL product (LYL845) with a greater expansion success rate across hot and cold tumors, improved product phenotype, and maintenance of TCR diversity (2022) (1)
IL-17A-Expressing CD4+ T Cells Must Acquire the Expression of T-Bet and IFN-γto Destroy Tumor Cells In Vivo. (2009) (1)
Non-apoptotic signaling through Fas activates Akt and promotes T cell differentiation through Caspase-8 (2017) (1)
Cancer genes disfavoring T cell immunity identified via integrated systems approach (2022) (1)
141 The Role of T Memory Stem Cells: Pathogenesis and Vaccines (2012) (1)
Abstract 1527: Integrated computational and experimental analysis identifies the mitochondrial uncoupling protein 2 (Ucp2) as a key regulator of T cell anti-tumor function (2021) (1)
CS11-4. Cish degradation of Htra1 regulates TGF-b signaling (2011) (1)
Abstract 1463: Ionic immune suppression within the tumor microenvironment limits T cell effector function (2016) (1)
Enhancing the recognition of tumor associated antigens (2009) (1)
Genome-Wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I and MHC-II Immunosurveillance in Human Lymphomas (2020) (1)
Causes Melanoma Eradication but not Vitiligo Genetic Vaccination with ''Self'' Tyrosinase-related Protein 2 (2000) (1)
and Induces Protective Immunity to Infectious and Humoral and Cellular Immune Responses CD40 Ligand/Trimer DNA Enhances Both (2013) (1)
Stem cells and cancer immunotherapy: Arrowhead’s 2nd annual cancer immunotherapy conference (2014) (1)
Identification of Novel Targets for Lung Cancer Therapy Using an Induced Pluripotent Stem Cell Model (2018) (1)
Modulating immunometabolism of tumor specific CD8 T cells to enhance T cell based therapy for cancer (2014) (1)
Definitive hematopoietic stem/progenitor cells from human embryonic stem cells through serum/feeder-free organoid-induced differentiation (2020) (1)
Cancer vaccines '98: a reductionistic approach. Bethesda, MD, USA, 27-28 April 1998. (1998) (1)
Mitochondrial activity regulates T cell memory, self renewal and anti tumor function in CD8+ T cells (2013) (1)
Translating new basic immunology into human immunotherapies: What works and what doesn’t (2005) (0)
PD-1 blockade reverts motility arrest of transferred tumor-infiltrating CD8+ T cells in adoptive cell transfer immunotherapy (TUM7P.1014) (2015) (0)
Abstract IA25: Identification of essential genes for cancer immunotherapy (2018) (0)
T cells and IFN-γ. These findings demonstrate that BACH2 is a key component of the molecular program of tumor immunosuppression and identify therapeutic targets for the reversal of immunosuppression in cancer. The transcription factor BACH2 promotes tumor immunosuppression (2016) (0)
Correction to: Definitive hematopoietic stem/progenitor cells from human embryonic stem cells through serum/feeder-free organoid-induced differentiation (2020) (0)
Fine-tuning T cell function through engineered orthogonal chimeric cytokine receptors (2022) (0)
a Peptide Vaccine Patients with Metastatic Melanoma Receiving Generation of Antitumor Reactivity in Impact of Cytokine Administration on the (1999) (0)
Inhibition of the T cell oxygen sensing machinery promotes anti-tumor efficacy (2015) (0)
77. Clinical Scale Zinc Finger Nuclease (ZFN)-Driven Gene-Editing of PD-1 in Tumor Infiltrating Lymphocytes (TIL) for the Potential Treatment of Metastatic Melanoma (2015) (0)
Cish actively silences tcr signaling in CD8+ T cells to maintain tumor tolerance (2015) (0)
Phase I S tudy o f t he I ntravenous A dministration o f Attenuated Salmonella t yphimurium to P atients W ith Metastatic M elanoma (2002) (0)
Abstract A078: Cutaneous microbiota in development of endogenous anti-melanocyte immunity (2016) (0)
Update on the Development of Curative Cancer Immunotherapies (2015) (0)
Suppressive Population of Mac-1 After Immunization : Induction of a T Lymphocytes + Apoptotic Death of CD 8 and (1998) (0)
Selective Rescue by Caspase Inhibition Tumor : Cells Following Activation by Specific Fas-Mediated Suicide of Tumor-Reactive T (1999) (0)
Faculty Opinions recommendation of Altered TCR signaling from geometrically repatterned immunological synapses. (2005) (0)
Faculty Opinions recommendation of Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. (2005) (0)
Insideblood ® 2 4 J a N U a R Y 2 0 1 3 I V O L U M E 1 2 1 , N U M B E R 4 (2013) (0)
Melanoma ' ' T Cells in Patients + Antigen-Specific CD 8 of Very High Levels of Self / Tumor Progression Can Occur despite the Induction Response to Comment on ' ' Tumor (2006) (0)
subsets possess superior traits for adoptive immunotherapy T cells derived from naive rather than memory + Human effector CD8 (2011) (0)
Toll-like Receptors inTumor Immunotherapy (2007) (0)
Immunotherapy generates selective pressure for acquisition of immunogenic neoantigens in escape tumors (2015) (0)
Conventional Endosomes and Is Influenced in Melanoma Cells Requires the Function of MHC Class II Presentation of gp100 Epitopes (2017) (0)
TEFF TEM TCM TSCM B cell Plasma cell MCPH (2014) (0)
Abstract 1347: Genomic stress in antigen experienced T-lymphocytes (2015) (0)
Correction to: Definitive hematopoietic stem/progenitor cells from human embryonic stem cells through serum/feeder-free organoid-induced differentiation (2020) (0)
217: BACH2 represses effector differentiation and cytokine expression to stabilize Treg-mediated immune homeostasis (2013) (0)
Destruction TumorUbiquitously while Mediating Specific T Cells Traffic Indiscriminately and + CD 8 Vaccine-Stimulated , Adoptively Transferred (2004) (0)
Virus Nucleoprotein Peptide Do Not Protect Mice (0)
Abstract SY03-02: Wnt signaling generates “stem-like” self-renewing T cells that can eradicate tumors (2010) (0)
Identifying Fas/CD95 non-apoptotic signaling pathways associated with T cell differentiation (2016) (0)
Anran Wang Cells That Can Self-Renew After Adoptive Transfer in Humans mRNA Defines Memory T γ The Stoichiometric Production of IL-2 and IFN (2012) (0)
CAN-10-0735 Cancer esearch oenvironment and Immunology or-Specific CD 8 + T Cells Expressing Interleukin-12 R dicate Established Cancers in Lymphodepleted Hosts (2010) (0)
Improving Adoptive Immunotherapy Using Less-Differentiated T Cells (2010) (0)
Induction of an acute vitamin A-deficient state following total body irradiation impairs anti-tumor immunity by altering the homeostasis of pre-cDC derived dendritic cells (2013) (0)
Activation of naïve CD8+ T cells by memory cells impairs antitumor immunity in adoptive cell transfer (2011) (0)
Identification of a feed-back circuit regulating the immune response and operating under different conditions of immunosuppression (1997) (0)
Stem cells and cancer immunotherapy (2014) (0)
Treatment of Large Established Murine Melanoma with Th17 Polarized CD4+ T Helper Cells Genetically Engineered to Express MHC Class IIRestricted T Cell Receptor (2008) (0)
Treatment of tumors with CD 4 + T cells Muranski and Restifo 201 Th cells in cancer immunity (2009) (0)
Engineering the immune response to "self" for effective cancer immunotherapy (2014) (0)
Author Correction: Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy (2021) (0)
Vaccines against virally induced cancers, Ciba Foundation Symposium 187 (1995) (0)
IL-7 and IL-15 can trigger cancer regression after adoptive transfer of CD8+T lymphocytes (2004) (0)
Fas expression in memory CD8+ T cell subsets augments cellular differentiation and effector function (2015) (0)
RecurrenceAntigen Loss Results in Murine Melanoma Regulatory T Cells and T Cell-Mediated Increased Frequency of Suppressive (2012) (0)
UK route of administration of recombinant vaccinia vitas (rVV) vaccines effects the active treatment of cancer (1996) (0)
The Cish SH2 domain is essential for PLC-γ1 regulation in TCR stimulated CD8+ T cells (2018) (0)
Hematopoietic Stem Cell Transplant With Lymphodepletion Augments T Cell-based Adoptive Immunotherapy (2005) (0)
Partly MHC Matched Allogeneic Tumor Specific T Cells Mediate Tumor Regression without Inducing GVHD in Immunosuppressed Host. (2006) (0)
Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for TCR and CAR based Adoptive Immunotherapy of Cancer (2016) (0)
Advisory Board and Contents (2021) (0)
Cish attenuates proximal TCR-signaling and CD8+ T cell immunity (2014) (0)
Abstract IA20: Sugar high: Glycolytic flux wrecks stem-cell like T cells. (2013) (0)
Modulating immunometabolism of tumor specific mouse and human lymphocytes to enhance T cell based therapy for cancer (2015) (0)
Erratum to: In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells (2011) (0)
Progress of cancer immunotherapy (CS-1) Chairpersons: Nicholas Restifo, Yutaka Kawakami (2010) (0)
Faculty Opinions recommendation of Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. (2002) (0)
This information is current as Occurring T Regulatory Cells T Helper Cells and Hindered by Naturally + Tumor/Self-Antigen Is Augmented by CD4 T Cell Immunity Against a + CD8 (2013) (0)
Ribosomal Proteins Regul ate MHC Class I Peptide Generation for Immunosurveillance Graphical (2019) (0)
Acquisition of Terminal Effector Functions In Vitro Impairs In Vivo Anti-Tumor Efficacy (2004) (0)
Abstract SY31-02: Building highly effective anti-tumor T cells (2014) (0)
immunization with a recombinant adenovirus Therapeutic antitumor response after (2001) (0)
Chemokine receptor targeting efﬁciently directs antigens to MHC class I pathways and elicits antigen-speciﬁc CD8 (cid:1) T-cell responses (2006) (0)
Precocious Differentiation of Somatic and Pluripotent Stem Cells Bearing Pre-Arranged TCR (2015) (0)
histocompatibility antigen Immunologic ignorance of vascular endothelial cells expressing minor (2013) (0)
Transgenic Mice Human gp100 Epitope Using DR4-IE Identification of a MHC Class II-Restricted (2000) (0)
Comment on Stemberger Et Al, Page 628 (0)
Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts (2018) (0)
BG2: Analysis of a T Cell Receptor Transgenic B6 Mouse Specific for B-Galactosidase (2009) (0)
Antigen-SpecificTumorVaccine Efficacy InVivo Against ProstateCancerwith LowClass IMHC (2002) (0)
targeting at tissue-specific enhancers by BRG 1 Regulation of nucleosome landscape and transcription factor Material Supplemental (2011) (0)
melanoma Tumor-specific Th17-polarized cells eradicate large established (2011) (0)
Hierarchy, tolerance, and dominance in the antitumor T-cell response. (2001) (0)
, The signal sequence peptide of the endoplasmic reticulum, and peptide-encode at least one other, their use in vaccines and to treat diseases (1994) (0)
THE USE OF RECOMBINANT POXVIRUSES AS A PARADIGM FOR THE DEVELOPMENT OF ANTI-CANCER VACCINES (1998) (0)
Maturation Dysregulating Antigen-Presenting Cell T Cell Responses by + Inhibits CD 8 Colony-Stimulating Factor by Tumors Granulocyte-Macrophage Unopposed Production (1999) (0)
Abstract 3966: Development of a fully-human chimeric antigen receptor against PSCA for the treatment of pancreatic cancer. (2013) (0)
Author response: The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells (2015) (0)
Th17-Derived Memory Cells Are Long-Lived and Retain a Stem-Like Molecular Signature (2010) (0)
obviates the requirement for in vivo vaccination T cells in vitro + Programming tumor-reactive effector memory CD8 (2013) (0)
IFN-gamma production by adoptively transferred CD8+ T lymphocytes and host cells contributes to successful tumor immunotherapy (2004) (0)
Procédés de production de populations de lymphocytes t à l'aide d'inhibiteurs d'akt (2016) (0)
IL12 polarization of mouse and human T‐cells: implications for adoptive immunotherapy (2008) (0)
Erratum: Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model (Journal of Immunotherapy (1999) 22 (489-496)) (2000) (0)
Faculty Opinions recommendation of Restoring function in exhausted CD8 T cells during chronic viral infection. (2006) (0)
Targeting Tyrosinase Engineered with a Highly Avid TCR Effective In Vivo Tumor Treatment When Both CD4 and CD8 T Cells Mediate Equally (2010) (0)
Treatment of Established B16 Murine Melanoma Tumors with Tyrp-1 Specific CD4+ Lymphocytes. (2006) (0)
Developing the Next Generation of iPSC Cell-Based Immunotherapies (2018) (0)
IL-2 Paradoxically Controls Tolerance and Immunity to A Tumor/Self-Antigen (2005) (0)
Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts (2017) (0)
Antigensof Autologous Melanoma Glycoprotein 100 and Does Not Alter the Recognition of Melanoma Tumor Antigen Primary Human Lymphocytes Affords Avid High Efficiency TCR Gene Transfer into (2013) (0)
65. CD4+ T Cell Immunity Following Gene Transfer Into Hematopoietic Stem Cells (2008) (0)
Crompton, Sukumar et al on Akt Cancer Res Jan 15 2015 (2015) (0)
Identification of Small Molecule Enhancers of Immunotherapy for Melanoma (2020) (0)
Advisory Board and Contents (2020) (0)
Toll-like receptor agonist therapy augments the antitumor activity of adoptively transferred CD8+ T cells without host preconditioning (2016) (0)
POLYMERIC STRUCTURE AND HOST TOLL-LIKE RECEPTOR 4 DICTATE THE IMMUNOGENICITY OF NY-ESO-1 IN VIVO (2011) (0)
Abstract 4034: Immunotherapy generates selective pressure to create an escape tumor with increased susceptibility to treatment with T cell based therapies (2016) (0)
Genome-wide profiling of druggable active tumor defense mechanisms to enhance cancer immunotherapy (2019) (0)
Ubiquitously while Mediating Specific Tumor CD8+ T Cells Traffic Indiscriminately and Vaccine-Stimulated, Adoptively Transferred (2013) (0)
Antigen , OA 1 Vivo to a Novel Self / Tumor Melanoma Tissue Enhances Human T Cell Responses In Normal Tissue Depresses While Tumor (2003) (0)
IL-12 induced Fas expression in myeloid-derived cells within tumors delivers a co-stimulatory signal for adoptively transferred CD8+ T cells (74.10) (2012) (0)
Advances in Brief Expression of a “ Self-” Antigen by Human Tumor Cells Enhances Tumor Antigen-specific CD 4 T-Cell Function (2002) (0)
A cleavage product of Polycystin-1 is a mitochondrial matrix protein that affects mitochondria morphology and function when heterologously expressed (2018) (0)
and normal B cells antigen receptor that recognizes murine CD19 can eradicate lymphoma Adoptive transfer of syngeneic T cells transduced with a chimeric (2013) (0)
The transcription factor c-Myb regulates CD8+ T cell stemness and antitumor immunity (2019) (0)
Abstract 4932: Oxygen sensing by T cells establishes an immunologically favorable metastatic niche (2017) (0)
Peptide-based polymer Toll-Like Receptor 7/8 agonist nanoparticles increase the breadth of anti-tumor CD8 T cell immunity (2017) (0)
Dissecting Antigen-Specific T-Cell Immunity in Human Cancer and Acquired Resistance to Immunotherapy (2016) (0)
The transcriptional program of vaccine-induced CD8 + T cell memory (2014) (0)
Abstract LB-242: Identification of T-cell receptors targeting KRAS-mutated human tumors (2016) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Nicholas P. Restifo?

Nicholas P. Restifo is affiliated with the following schools: